Omega Therapeutics, Inc.
OMGAQ
$0.038
-$0.007-15.56%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 184.93% | 142.38% | 112.70% | 49.23% | 91.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 184.93% | 142.38% | 112.70% | 49.23% | 91.57% |
| Cost of Revenue | -42.71% | -43.68% | -25.94% | -14.37% | 20.94% |
| Gross Profit | 51.01% | 49.36% | 29.87% | 16.10% | -19.34% |
| SG&A Expenses | 10.36% | 32.06% | 39.81% | 36.57% | 20.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.45% | -25.18% | -10.02% | -1.42% | 20.68% |
| Operating Income | 32.91% | 29.03% | 12.64% | 2.44% | -19.54% |
| Income Before Tax | 32.35% | 29.30% | 14.41% | 5.13% | -16.51% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 32.35% | 29.30% | 14.41% | 5.13% | -16.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.35% | 29.30% | 14.41% | 5.13% | -16.51% |
| EBIT | 32.91% | 29.03% | 12.64% | 2.44% | -19.54% |
| EBITDA | 33.57% | 29.65% | 12.90% | 2.48% | -19.91% |
| EPS Basic | 36.45% | 35.59% | 24.70% | 15.73% | -7.57% |
| Normalized Basic EPS | 36.46% | 35.59% | 24.72% | 15.73% | -7.57% |
| EPS Diluted | 36.27% | 35.41% | 24.66% | 15.68% | -7.61% |
| Normalized Diluted EPS | 36.46% | 35.59% | 24.72% | 15.73% | -7.57% |
| Average Basic Shares Outstanding | 5.68% | 9.50% | 13.53% | 12.84% | 9.12% |
| Average Diluted Shares Outstanding | 5.68% | 9.50% | 13.53% | 12.84% | 9.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |